$AMGN — HOLD 📊 | 6 MONTHS THESIS

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. 🎯 FQ2 FY2026 (ends Jun) | reported Aug 04 | Rev $10.1B | Adj EPS $6.29 vs $5.62 🟢 | GAAP EPS $4.40 💡 The market priced in -0.2% FCF growth per reverse DCF, yet the earnings beat may lead to upward revisions. However, the current valuation at 15.5x run-rate P/E is near the high end of the peer band (9.4-16x), suggesting expectations have already caught up. 🏢 Business Quality: 7/10 📊 Valuation: fair — 15.5x run-rate P/E, 16.6x forward P/E, 27.2x GAAP TTM; reverse DCF implies -0.2% FCF growth; historical PE at 100th percentile. 🔮 Catalyst: FQ2 FY2026 earnings reported on Aug 04 ⚖️ Hold — strong earnings beat but the valuation offers no edge; wait for a better entry or a clear catalyst that reprices growth expectations. 📊 Our read: HOLD. Full analysis → https://stockduty.xyz/s/AMGN0805 Also in play: $LLY $JNJ $ABBV $UNH $MRK

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.